Cargando…

EGFR-mutated lung cancer: a paradigm of molecular oncology

The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. EGFR-mutated adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhenfeng, Stiegler, Amy L., Boggon, Titus J., Kobayashi, Susumu, Halmos, Balazs
Formato:	Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2010
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001953/ https://www.ncbi.nlm.nih.gov/pubmed/21165163

Ejemplares similares

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

p190RhoGAP proteins contain pseudoGTPase domains
por: Stiegler, Amy L., et al.
Publicado: (2017)

Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2019)

Correction: Crystal structures of p120RasGAP N-terminal SH2 domain in its apo form and in complex with a p190RhoGAP phosphotyrosine peptide
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2020)

Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP, and Dok1
por: Vish, Kimberly J., et al.
Publicado: (2023)

SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP
por: Chau, Jocelyn E., et al.
Publicado: (2022)

Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
por: Zhang, Zhenfeng, et al.
Publicado: (2012)

Revolving Door of Histologic Transformation—Tumor Heterogeneity Complicating the Management of EGFR-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde
por: Wysota, Michael, et al.
Publicado: (2020)

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer
por: Wang, Feng, et al.
Publicado: (2019)

Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
por: Ikemura, Shinnosuke, et al.
Publicado: (2019)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko, Brian, et al.
Publicado: (2017)

EGFR Mutations and Lung Cancer
Publicado: (2005)

Purification and SAXS Analysis of the Integrin Linked Kinase, PINCH, Parvin (IPP) Heterotrimeric Complex
por: Stiegler, Amy L., et al.
Publicado: (2013)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
por: Kagawa, Yosuke, et al.
Publicado: (2023)

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer
por: Sueoka-Aragane, Naoko, et al.
Publicado: (2015)

Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
por: Tang, Zhe, et al.
Publicado: (2008)

Germline EGFR mutations in lung cancer (Review)
por: Liu, Minghui, et al.
Publicado: (2023)

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
por: Vasconcelos, Pedro E.N.S., et al.
Publicado: (2020)

How SOLID is the immune system’s response to the deadly duo of lung cancer and SARS-CoV-2?
por: Narvel, Hiba, et al.
Publicado: (2022)

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
por: Hirano, Toshiyuki, et al.
Publicado: (2015)

AXL kinase as a novel target for cancer therapy
por: Wu, Xiaoliang, et al.
Publicado: (2014)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Future paradigms for precision oncology
por: Klement, Giannoula Lakka, et al.
Publicado: (2016)

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
por: Reita, Damien, et al.
Publicado: (2021)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
por: Jorge, S.E.D.C., et al.
Publicado: (2014)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

EGFR mutation testing from pleural effusions of non-small cell lung cancer patients at the institute for oncology and radiology of Serbia
por: Vukovic, Miodrag, et al.
Publicado: (2023)

Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation
por: Romberg, Neil, et al.
Publicado: (2014)

Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population
por: Berois, Nora, et al.
Publicado: (2017)

Model for predicting EGFR mutation status in lung cancer
por: Nguyen Ho, Lam, et al.
Publicado: (2019)

Potential of combination therapy in EGFR mutated lung cancer
por: Maemondo, Makoto
Publicado: (2020)

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Systems oncology: A new paradigm in cancer research
por: Kovvali, Gopala
Publicado: (2014)

Predictive radiogenomics modeling of EGFR mutation status in lung cancer
por: Gevaert, Olivier, et al.
Publicado: (2017)

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates
por: Sentana-Lledo, Daniel, et al.
Publicado: (2023)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
por: Kobayashi, Ikei S., et al.
Publicado: (2021)

Molecular pathways to therapeutics: Paradigms and challenges in oncology meeting report: Carcinogenesis 2015
por: Warawdekar, Ujjwala M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nfc82i3dtd43efnr01v92fe6ss